AU2018301701A1 - Encapsulated polynucleotides and methods of use - Google Patents

Encapsulated polynucleotides and methods of use Download PDF

Info

Publication number
AU2018301701A1
AU2018301701A1 AU2018301701A AU2018301701A AU2018301701A1 AU 2018301701 A1 AU2018301701 A1 AU 2018301701A1 AU 2018301701 A AU2018301701 A AU 2018301701A AU 2018301701 A AU2018301701 A AU 2018301701A AU 2018301701 A1 AU2018301701 A1 AU 2018301701A1
Authority
AU
Australia
Prior art keywords
mir
recombinant dna
dna molecule
virus
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018301701A
Other languages
English (en)
Inventor
Mitchell H. Finer
Edward Kennedy
Lorena Lerner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elevatebio Technologies Inc
Original Assignee
Elevatebio Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elevatebio Technologies Inc filed Critical Elevatebio Technologies Inc
Publication of AU2018301701A1 publication Critical patent/AU2018301701A1/en
Assigned to ELEVATEBIO TECHNOLOGIES, INC. reassignment ELEVATEBIO TECHNOLOGIES, INC. Request for Assignment Assignors: ONCORUS, INC.
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32041—Use of virus, viral particle or viral elements as a vector
    • C12N2770/32043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2018301701A 2017-07-14 2018-07-13 Encapsulated polynucleotides and methods of use Abandoned AU2018301701A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762532886P 2017-07-14 2017-07-14
US62/532,886 2017-07-14
US201862648651P 2018-03-27 2018-03-27
US62/648,651 2018-03-27
PCT/US2018/042136 WO2019014623A1 (en) 2017-07-14 2018-07-13 Encapsulated polynucleotides and methods of use

Publications (1)

Publication Number Publication Date
AU2018301701A1 true AU2018301701A1 (en) 2020-02-27

Family

ID=65002120

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018301701A Abandoned AU2018301701A1 (en) 2017-07-14 2018-07-13 Encapsulated polynucleotides and methods of use

Country Status (13)

Country Link
US (1) US20200224220A1 (cg-RX-API-DMAC7.html)
EP (1) EP3652325A4 (cg-RX-API-DMAC7.html)
JP (2) JP2020530778A (cg-RX-API-DMAC7.html)
KR (1) KR20200036873A (cg-RX-API-DMAC7.html)
CN (1) CN111212914A (cg-RX-API-DMAC7.html)
AU (1) AU2018301701A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020000839A2 (cg-RX-API-DMAC7.html)
CA (1) CA3069821A1 (cg-RX-API-DMAC7.html)
IL (1) IL271969A (cg-RX-API-DMAC7.html)
MX (1) MX2020000495A (cg-RX-API-DMAC7.html)
RU (1) RU2020106730A (cg-RX-API-DMAC7.html)
SG (1) SG11202000312UA (cg-RX-API-DMAC7.html)
WO (1) WO2019014623A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020000993A (es) 2017-07-26 2020-07-22 Oncorus Inc Vectores virales oncolíticos y usos de estos.
MX2020001593A (es) 2017-08-09 2020-07-13 Bioverativ Therapeutics Inc Moleculas de acido nucleico y usos de las mismas.
SG11202006457YA (en) 2018-01-05 2020-08-28 Ottawa Hospital Res Inst Modified orthopoxvirus vectors
US20200405791A1 (en) * 2018-03-12 2020-12-31 Mayo Foundation For Medical Education And Research Using infectious nucleic acid to treat cancer
JP7602454B2 (ja) 2018-08-09 2024-12-18 バイオベラティブ セラピューティクス インコーポレイテッド 核酸分子及び非ウイルス遺伝子治療のためのそれらの使用
DK3864163T3 (da) 2018-10-09 2024-05-06 Univ British Columbia Sammensætninger og systemer omfattende transfektionskompetente vesikler fri for organiske opløsningsmidler og rengøringsmidler og fremgangsmåder forbundet dermed
CA3117924A1 (en) * 2018-11-13 2020-05-22 Oncorus, Inc. Encapsulated polynucleotides and methods of use
CA3124524A1 (en) * 2019-01-04 2020-07-09 Oncorus, Inc. Encapsulated rna polynucleotides and methods of use
US12209250B2 (en) * 2019-03-14 2025-01-28 Massachusetts Institute Of Technology Engineered Herpes Simplex Virus-1 (HSV-1) vectors and uses thereof
JP2022543610A (ja) * 2019-08-05 2022-10-13 ヴァイロジン バイオテック カナダ リミテッド 遺伝子改変エンテロウイルスベクター
CN114765990A (zh) * 2019-10-10 2022-07-19 昂克诺斯公司 双重病毒和双重溶瘤病毒以及治疗方法
EP4157456A4 (en) * 2020-05-29 2024-06-26 Oncorus, Inc. ENCAPSULATED RNA REPLIKONS AND METHODS OF USE
EP4164596A1 (en) * 2020-06-11 2023-04-19 eTheRNA Immunotherapies NV Lipid nanoparticles
US20230242994A1 (en) * 2020-07-10 2023-08-03 Shanghai Miran Biotech Co., Ltd. Fluorescent cross-linked rnase h mutant conjugate, mirna combination and application thereof
CA3204244A1 (en) * 2021-01-06 2022-07-14 Lorena Lerner Encapsulated rna polynucleotides and methods of use
CN113368261A (zh) * 2021-06-17 2021-09-10 苏州大学 一种非病毒载体及其制备方法与应用
WO2023069948A1 (en) 2021-10-18 2023-04-27 Flagship Pioneering Innovations Vii, Llc Dna compositions and related methods
US20250304999A1 (en) * 2022-05-20 2025-10-02 Virogin Biotech Canada Ltd Genetically modified enterovirus vectors with enhanced genomic stability
JP7229412B1 (ja) 2022-06-14 2023-02-27 キユーピー株式会社 脂質ナノ粒子及びその製造方法
CN118634240A (zh) * 2022-06-27 2024-09-13 浙江大学 抗口腔肿瘤药物活性成分及其用途
KR20260043572A (ko) * 2024-09-24 2026-03-31 고려대학교 산학협력단 폐암 치료를 위한 페메트렉시드-기능화 종양 미세환경 표적 흡입용 약물전달시스템

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004274860A1 (en) * 2003-05-28 2005-03-31 Wisconsin Alumni Research Foundation Recombinant influenza vectors with a polII promoter and ribozymes
DK1668025T3 (da) * 2003-09-26 2014-08-25 Novartis Ag Seneca Valley-virusbaserede præparater og fremgangsmåder til behandling af sygdom
US7473418B2 (en) * 2004-03-25 2009-01-06 Cell Genesys, Inc. Pan cancer oncolytic vectors and methods of use thereof
GB0810912D0 (en) * 2008-06-13 2008-07-23 Inst Animal Health Ltd Vector
DK2346995T3 (en) * 2008-09-26 2019-02-11 Tocagen Inc GENETERIVE VECTORS AND CYTOSINDEAMINASES
CA2782366A1 (en) * 2009-12-16 2011-07-14 Opko Curna, Llc Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1
WO2013083753A2 (en) * 2011-12-07 2013-06-13 Institut Pasteur Identification of a swine parecho-like virus and applications
WO2013156989A1 (en) * 2012-04-18 2013-10-24 Ramot At Tel-Aviv University Ltd. Lipidated glycosaminoglycan particles for the delivery of nucleic acids
WO2014171526A1 (ja) * 2013-04-17 2014-10-23 国立大学法人九州大学 遺伝子改変コクサッキーウイルス
US10513711B2 (en) * 2014-08-13 2019-12-24 Dupont Us Holding, Llc Genetic targeting in non-conventional yeast using an RNA-guided endonuclease
HK1246183A1 (zh) * 2015-06-10 2018-09-07 Hookipa Biotech Gmbh Hpv疫苗
WO2017096201A1 (en) * 2015-12-02 2017-06-08 Memorial Sloan-Kettering Cancer Center Seneca valley virus (svv) cellular receptor targeted oncotherapy

Also Published As

Publication number Publication date
BR112020000839A2 (pt) 2020-07-21
JP2020530778A (ja) 2020-10-29
EP3652325A4 (en) 2021-09-15
SG11202000312UA (en) 2020-02-27
IL271969A (en) 2020-02-27
CN111212914A (zh) 2020-05-29
KR20200036873A (ko) 2020-04-07
RU2020106730A (ru) 2021-08-16
EP3652325A1 (en) 2020-05-20
CA3069821A1 (en) 2019-01-17
US20200224220A1 (en) 2020-07-16
JP2023165916A (ja) 2023-11-17
WO2019014623A1 (en) 2019-01-17
MX2020000495A (es) 2020-08-20

Similar Documents

Publication Publication Date Title
US20200224220A1 (en) Encapsulated polynucleotides and methods of use
US20210403950A1 (en) Encapsulated polynucleotides and methods of use
JP7652823B2 (ja) 腫瘍溶解性ウイルスベクター及びその使用
US20220117902A1 (en) Encapsulated rna polynucleotides and methods of use
TWI798168B (zh) 溶瘤病毒載體及其用途
JP5652830B2 (ja) マイクロrna制御組換えワクシニアウイルス及びその使用
AU2022206676A1 (en) Encapsulated rna polynucleotides and methods of use
CN119233824A (zh) 编码小核糖核酸病毒的rna多核苷酸的产生
HK40029850A (en) Encapsulated polynucleotides and methods of use
HK40083636B (en) Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids
da Costa MicroRnas as Molecular Targets for Non-Viral Gene Therapy of Glioblastoma: Development of a Lipid-Based Nanosystem for Nucleic Acid Delivery to Brain Tumor Cells
HK40083636A (en) Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: ELEVATEBIO TECHNOLOGIES, INC.

Free format text: FORMER APPLICANT(S): ONCORUS, INC.

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application